TY - JOUR
T1 - Diabetic Macular Edema Treated with Anti–Vascular Endothelial Growth Factor: Considerations Related to Nonimprovers
AU - Hodzic-Hadzibegovic, Delila
AU - Sander, Birgit Agnes
AU - Valerius, Marianne
AU - Lund-Andersen, Henrik
PY - 2018/11
Y1 - 2018/11
N2 - Purpose To investigate central subfield thickness (CST) nonimprovers’ anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with
AB - Purpose To investigate central subfield thickness (CST) nonimprovers’ anatomic response in macular areas outside the central subfield and the time course of this response. Furthermore, to investigate the relationship between peripheral improvement and visual acuity. Design Retrospective study. Participants A total of 566 eyes in 566 patients with center-involved diabetic macular edema who initiated intravitreal treatment with ranibizumab between January 1, 2011 and December 31, 2013 in the Greater Copenhagen Region. Follow-up was completed at 2 years. Methods Patients were initially grouped as CST improvers and CST nonimprovers. The CST improvers had a ≥10% reduction in CST on ≥1 visit as opposed to CST nonimprovers with
U2 - 10.1016/j.oret.2018.04.026
DO - 10.1016/j.oret.2018.04.026
M3 - Journal article
C2 - 31047551
SN - 2468-6530
VL - 2
SP - 1133
EP - 1142
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 11
ER -